Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track EVAX with free AI briefings, catalyst countdowns, and dilution alerts.

EVAX · Evaxion A/S

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$14M Cash on Hand
23.5mo Cash Runway
Follow EVAX by email Get an email when EVAX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about EVAX, unsubscribe in one click. Privacy

📣 What EVAX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Personalized Liposomal Neoantigen-based Peptide… Melanoma Stage IV Phase 2 · NCT05309421 Completed
EVX-02A Melanoma Stage IV Phase 1/2 · NCT04455503 Terminated
EVX-02A OR EVX-02B Melanoma Stage IV Phase 1/2 · NCT04455503 Terminated
EVX-02B Melanoma Stage IV Phase 1/2 · NCT04455503 Terminated

Also used in these trials (approved or third-party drugs, not EVAX's own candidates): Pembrolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

EVAX holds $14M in cash and short-term investments and burns about $1.8M/quarter from operations, an estimated runway of 23.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 33 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when EVAX files for a raise →

👥 Who Owns EVAX

Insiders 3.3% Institutions (19 holders) 9.5% Public and other holders 87.2%
HolderTypeShares% of sharesAs of
Andreas Holm Mattsson
CAIO Chief AI Officer
Insider 5,524,916 1.32% 2026-03-18
Marianne Soegaard
Director
Insider 3,863,115 0.93% 2026-03-18
Helen Katrina Tayton-martin
Chief Executive Officer
Insider 2,286,150 0.55% 2026-03-18
A/S Evaxion
Chief Executive Officer
Includes shares also reported by Helen Katrina Tayton-martin, counted once
Insider 2,286,150 0.55% 2026-03-18
Roberto Prego
Director
Insider 1,171,030 0.28% 2026-03-18
Thomas Frederik Schmidt
Chief Financial Officer
Insider 645,750 0.15% 2026-03-18
Lars Holtug
Director
Insider 258,029 0.06% 2026-03-18
Lars Aage Staal Wegner
Director
Insider 129,139 0.03% 2026-03-18
Birgitte Rono
Chief Scientific Officer
Insider 36,765 0.01% 2026-03-18
Jens Bitsch-Norhave
Director
Insider 2,376 0.00% 2026-04-16

Share count 417,010,756 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full EVAX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EVAX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.